We’re excited to announce IREX-Lung as part of the IASLC.
A global, multidisciplinary group focused on advancing exercise research in lung cancer!
Projects launching soon! Interested in contributing or proposing ideas? Get in touch!
#IREXLung#ExerciseOncology
We’re excited to announce IREX-Lung as part of the IASLC.
A multidisciplinary group focused on advancing exercise research in lung cancer!
Projects launching soon! Interested in contributing or proposing ideas? Get in touch!
#IASLC#IREXLung#ExerciseOncology#LungCancerResearch
🎉 Today is a very special day for us!
The @STARLighT project (@AIRC_it) was featured on @Rai1 – Check Up: a huge satisfaction and a recognition for the work of an amazing team 👩🔬
🎯 Our goal? To make lifestyle an integral part of the care pathway, alongside medical treatments.
Just published in @SportsMedicineJ. We explore how bringing the principles of periodization in exercise medicine can transform it into a precisely targeted therapy, by tailoring mode, volume, and intensity based on cancer type, stages, and treatments @ProfRobNewton@Doc_Haff
Excited to share our work published in Journal of Cancer Survivorship. Exercise can reduce chronic inflammation and changes induced by exercise on body composition could mediate the inflammatory response. This reduces cancer development and recurrence.
@ProfRobNewton@EMRI_ECU
Just published by our team at the @EMRI_ECU at @EdithCowanUni and led by @FBettariga.
Changes in body composition following exercise were not consistently associated with inflammatory biomarker responses in breast cancer survivors with only LM significantly associated with IL-6 while a trend in LM and FM existed for some other inflammatory markers. Although these findings do not provide conclusive evidence, they highlight a possible role of exercise-induced body composition changes in mediating inflammation. Further research is needed to clarify whether targeted exercise interventions that improve body composition can contribute to reducing inflammation and, ultimately, impact breast cancer progression, recurrence, and mortality.
https://t.co/V3dno4cZ11
Many thanks to co-authors: Dennis Taaffe, Anita Borsati , Alice Avancini, Sara Pilotto, Stefano Lazzarini, Pedro Lopez, @lucamae1987, @umbertocrainich, Enrico Bandini, John Campbell, Tim Clay, and Daniel Galvao.
Presented at #ASCO25:
A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial results: https://t.co/j3kWJDjuVz
@ASCO
#ASCO25@asco@CDNCancerTrials 🇨🇦 C0.21 CHALLENGE trial
- ‘first-in-class’ RCT of 3y structured exercise program (>10 METhr/wk) vs education in stage 2/3 colon cancer after surgery & AT - Dr. Chris Booth
📌 N=889, 6 countries (>60% 🇨🇦), 90% stg 3
📌 improved DFS, HR 0.72 (p=0.0
📌 ⬆️ OS - 37% reduction in risk of death, NNT 14 at 8y
Amazing news for our patients 🤗
‼️recommending exercise is not enough - we need to support a behavior change with coaching and training🚶
Simultaneous @NEJM
@GICancer 🇦🇺🇳🇿
@BCCancer@UBCNews@ccranorg@coloncanada
#PlenaryMiss
✅ Exercise Saves Lives After Colon Cancer🚶
What if this was a drug ?🙂
🆕 NEJM | June 2025
🎯 CHALLENGE Trial: Structured exercise after adjuvant chemo in colon cancer
📦 RCT | n=889 | Median FU: 7.9 yrs
🟠 3-yr structured aerobic program vs health ed alone
📈 Primary Endpoint: Disease-Free Survival (DFS)
🔹 HR 0.72 (95% CI: 0.55–0.94), p=0.02
🔹 5-yr DFS: 80.3% vs 73.9% (+6.4%)
🟨 Overall Survival (OS)
🔸 HR 0.63 (95% CI: 0.43–0.94)
🔸 8-yr OS: 90.3% vs 83.2% (+7.1%)
🧠 Other highlights:
🔻 ↓ Liver recurrence: 3.6% vs 6.5%
🔻 ↓ New primary cancers: 5.2% vs 9.7%
🔻 Improved cardiorespiratory fitness, QoL, 6-min walk
⚠️ AEs: ↑ MSK issues (18.5% vs 11.5%), mostly mild
No major safety concerns
🤔 What if this was a drug?
📢 “Breakthrough”
💰 $120K/year
📄 Fast-track approval
Instead, it’s just structured EXERCISE.
💡 Prescribe it like we would any other adjuvant therapy.
Congratulations to Authors and Dr Chris Booth 👏
#CHALLENGEtrial #ASCO25 @csoncol@oncology_bg@ASCO #ASCO25 @OncoAlert